Fig. 7: Comparison of SARS-CoV-2–specific humoral responses in PLWH and HCWs receiving the original–BA.4/5 bivalent booster.
From: Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
Fold-increase (T1/T0 ratio) and fold-decrease (T1/T2 ratio) of total RBD-binding (a, b) and RBD-blocking antibodies (d, e) against WT and BA.4/5 virus in PLWH (nT1/T0 = 29, nT1/T2 = 23) and HCWs (n = 19) receiving the bivalent booster. Values equals to 1 indicate no increase/decrease, while values higher than 1 indicate an increase/decrease. Green/orange circles and hexagons: individual values; black bars: median values; green/orange boxes: interquartile ranges; statistical analyses: Mann–Whitney test (comparison between PLWH and HCWs; P values < 0.05 showed in green or orange above solid lines) and Wilcoxon test (comparison between WT- and BA.4/5-reactive antibodies; P values < 0.05 showed in black above dashed lines). c, f Multivariable linear regression analysis exploring the association between HIV status (independent variable) and RBD-binding/blocking antibodies fold-change (dependent variable) adjusted for potential confounders as specified below the forest plot. Green/orange circles: β coefficient; black error bars: 95% confidence interval (CI).
